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Galectins are involved in many cellular processes due to their ability to
bind carbohydrates. Understanding their functions has shown the necessity
for potent and speciﬁc galectin inhibitors. Human galectin-7 (hGal-7), in
particular, has been highlighted as an important marker in many types of
cancer by either inhibiting or promoting tumour growth. Producing ligands
able to selectively target hGal-7 will offer promising tools for deciphering
cancer processes in which hGal-7 is involved as well as present potential
solutions for future therapeutics. Here we report the high resolution crystal
structure of hGal-7 in complex with a synthetic 2-O-benzylphosphate-galac-
toside inhibitor (which is > 60-fold more potent than its parent galacto-
side). The high resolution crystallographic analysis highlights the validity
of using saccharide derivatives, conserving properties of the galactose bind-
ing, while enhanced afﬁnity and speciﬁcity is provided by the added phos-
phate group. This structural information will allow the design of further
inhibitors with improved potency and speciﬁcity.
Database
The atomic coordinates for the complex of human galectin-7 as well as for the free structure
have been deposited with the Protein Data Bank (accession numbers 3ZXE and 3ZXF respec-
tively)
Structured digital abstract
l hGal-7 and hGal-7 bind by X-ray crystallography (View interaction)
Introduction
Galectins are members of the carbohydrate-binding
lectin family with speciﬁcity for b-galactosides. They
have in common a carbohydrate recognition domain
(CRD) and signiﬁcant sequence similarity [1]. So far
15 mammalian galectins have been identiﬁed; they are
classiﬁed in three subunit types based on their CRD
architecture: prototype (galectin-1, -2, -5, -7, -10, -11,
-13, -14, -15), tandem repeat type (galectin-4, -6, -8, -9,
-12) and chimera-type (galectin-3) [2]. The CRD is
about 130 amino acids long, and the b-galactoside
binding site is conserved among galectins, while differ-
ences both in adjacent b-strands and loop regions
explain the variation in oligosaccharide binding afﬁn-
ity [3,4].
These lectins are expressed by a wide range of cell
types and can be found from the nucleus to the
Abbreviations
CRD, carbohydrate recognition domain; hGal-7, human galectin-7.
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space. They display various physiological roles in
development, infection [5] and immunity [6] and
have increasingly been linked with cancers [7]. The
extent of galectin roles in these mechanisms is still
unclear as they are involved in many cell–cell and
cell–matrix interactions, as well as intracellular pro-
cesses [8–10].
Understanding the role of galectins has raised the
need for potent and selective inhibitors, which will be
valuable tools for drug design in the treatment of
galectin-mediated pathologies. The multivalence of
galectins and the common CRD motif with different
speciﬁcities towards particular carbohydrates are the
keys to the function of these proteins. Several
approaches have been successful in giving evidence
towards the targeting of galectins for cancer treatment,
such as the inhibition of metastasis with anti-galectin-3
monoclonal antibody in breast cancer cells [11]. The
use of small molecules capable of directly binding the
CRD seems like the most attractive option and has
been demonstrated by speciﬁc synthetic peptides and
carbohydrate-based inhibitors in malignant endothelial
cells [12,13] and small molecule inhibitors in papillary
thyroid cancer [14]. More recently galectin-1, a proto-
type galectin, was also identiﬁed as a target of choice
for stopping cancer progression [15,16].
Human galectin-7 (hGal-7) is a 15 kDa prototype
galectin with a single CRD, monomeric but capable of
dimerization in solution [17]. It was ﬁrst reported in an
effort to identify markers of keranocyte differentiation
[18]. Galectin-7 involvement in the maintenance of the
pluristratiﬁed epithelia and epidermal stratiﬁcation [19]
has highlighted its role in wound healing. It was proven
to be an efﬁcient growth factor with therapeutic implica-
tions [20]. Some of the more recent advances on galec-
tin-7 have shown its implication in apoptose induction
in various types of cell. Galectin-7 expression is induced
upon UV radiation [21] and regulated by p53, therefore
showing high levels in certain types of cancer. Conse-
quently galectin-7 has shown major roles in cancer
development, by helping either in the elimination of cer-
tain tumour types [22] or in the growth stimulation of
others [23,24]. Galectin-7 was recently described as a
key element in aggressive metastasis following its over-
expression in breast carcinomas and thus represents an
interesting molecule as a marker for this pathology, and
also as a therapeutic target [25].
The crystal structure of hGal-7 and its recognition of
a range of carbohydrates have been described [26]. The
crystal structure (PDB code 1BKZ) showed a dimeric
arrangement allowing for the CRD presentation, which
was conﬁrmed by the structures of complexes with
galactose, galactosamine, lactose and N-acetyllactos-
amine (PDB codes 2GAL, 3GAL, 4GAL and 5GAL
respectively). The detailed map of hGal-7 binding to
carbohydrates identiﬁed the key residues involved in
the CRD and provided clues to the protein function as
well as opening the way for current research into the
design of small molecule inhibitors.
Salameh et al. [27] presented the synthesis of C3¢-thio
ureido N-acetyllactosamine derivatives and Cumpstey
et al. [28] that of substituted phenyl thio-b-D-galacto-
pyranosides, both of which were potent inhibitors of
galectin-7 with improved binding afﬁnity to reported
natural saccharides. Such designed ligands based on
the galectin key afﬁnity for galactose in combination
with additional structural moieties that can interact
with the CRD and surrounding unexploited sub-sites
allows for optimization of afﬁnity and speciﬁcity.
Following such a design strategy, a series of 2- and
3-O-substituted galactosides 2–6 were recently synthe-
sized and evaluated as inhibitors against a panel of
galectins [29]. In this study, galectin-7 inhibition was
enhanced by a 3-C-benzamido substitution of galacto-
sides; cf. 1 and 2 (Table 1). Furthermore, addition of
anionic 2-O-substituents to obtain a 2-O-(H-phospho-
nate) 3 and 2-O-alkylphosphate substituents (5, 6) pro-
vided signiﬁcantly enhanced binding to galectin-7,
while a 2-O-phosphate 4 proved to enhance the afﬁnity
to a lesser extent for galectin-7. Together with phenyl
thio-b-D-galactopyranosides [27] compounds 3 and 5, 6
belong to the most potent monosaccharide inhibitors
described for galectin-7. The three-dimensional struc-
ture of galectin-7 in complex with these newly designed
inhibitors, such as the 2-O-benzylphosphate 6, will
help address the structural basis of the molecules’
inhibitory action, offer a platform for improving their
speciﬁcity and become the template for efﬁcient drug
design. Here we report the improved high resolution
crystal structure of hGal-7 at 1.4 A ˚ , and its 1.7 A ˚
structure in complex with the 2-O-benzylphosphate
inhibitor 6.
Results
Overall structure
The crystal structure of hGal-7 in complex with a
novel inhibitor was determined at 1.7 A ˚ , along with a
higher resolution structure (1.4 A ˚ ) of the native form.
In both cases, hGal-7 crystallized as a dimer in the
P212121 space group, although the presence of the
inhibitor changed the unit cell dimensions from
a = 54.30, b = 65.11, c = 70.83 A ˚ to a = 35.3,
b = 53.5, c = 138.6 A ˚ respectively (Table 2). The
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monomers) interaction is similar in both cases (Fig. 1).
It was observed on SDS⁄PAGE and gel ﬁltration chro-
matography that hGal-7 can form a dimer in solution
as well as being present in its monomeric form (results
not shown); others showed the dimer by analytical ul-
tracentrifugation [17]. A PISA analysis [30] of the
dimeric state in the crystal structure indicates that the
interface area of 797 A ˚ 2 is potentially associated with
15 hydrogen bonds and 20 salt bridges; thus this inter-
action is probably due to crystallographic packing.
The high resolution (1.4 A ˚ ) structure gives an accu-
rate insight into the molecular architecture of the
protein with 99.3% of residues in the favoured Rama-
chandran plot area and 336 water molecules observed.
The overall ‘jelly-roll’ fold is conserved compared with
the previously obtained native and carbohydrate-bound
complex structures. The two molecules in the asymmet-
ric unit have similar overall characteristics (rmsd of
0.73 A ˚ for all atoms) with little differences observed in
some previously disordered regions. At the N-termini in
particular molecule B presented some residual amino
acids from the histidine-tag cleavage (Fig. 1) forming a
tail lodging itself between two crystal-related symmetry
molecules. Compared with the available structure, resi-
dues 1–3 were well ordered in both chains as well as
Pro10 and Glu11. The CRD itself remains unchanged
despite a slight movement in the adjacent loop com-
posed of Arg74 and Gly75. This is in analogy to the
recent observation that galectin-3 CRD remains largely
unchanged upon ligand binding [31]. This solvent acces-
sible region is stabilized thanks to hydrogen bonds and
salt bridges with the surrounding residues (Glu58,
Glu72) and with a symmetry-related molecule in mole-
cule A only, while an extensive network of water mole-
cules is present at the ligand binding site. Six residues
showed potential alternate side chain conformation,
namely Val18, Leu89, Asp95, Arg110, Arg117 and
Arg133. None of these residues is known to be involved
in ligand binding.
Molecule A had an unusual difference electron
density around the buried thiol group (Cys38), which
is not conserved among galectins (Fig. S1). Cyste-
ine was replaced with an S-oxy cysteine in the struc-
ture, with potential oxidation due to radiation
damage. This solvent accessible cysteine residue is
not known to be involved in any biological function.
2-O-Benzylphosphate galactoside inhibitor 6
binding to hGal-7
The native protein does not show any major conforma-
tional change upon binding to the inhibitor 6 with an
Table 1. Afﬁnity of carbohydrate derivative inhibitors for hGal-7
(1–6 [29]; 7 [32]). Kd values are the average and standard deviation
of repeated single point measurements at 4  C.
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a Estimated from the highest non-inhibitory concentration used.
b Estimated from emerging inhibitory effects at higher inhibitor con-
centrations.
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ture was solved to 1.7 A ˚ (Rwork = 20.4%, Rfree =
23.9%, with 98.5% Ramachandran favoured) and
electron density was clearly visible for the small mole-
cule inhibitor in molecule B (Fig. 2), while only partial
density could be seen in molecule A. The galactose
moiety shows similar binding property to that of the
galactose monomer (PDB 2GAL, Fig. 3) including the
six main potential hydrogen interactions (Table 3).
However, the high resolution structure highlights
stronger binding achieved through the side groups of
the 2-O-benzylphosphate inhibitor 6. The phosphate
group has a weak hydrogen bonding potential with
Arg31, while it is also stabilized by hydrogen-bonded
water molecules linked to the same Arg31 and Asn51.
The amido group also shows potential interactions with
water molecules linked to Lys64 and Trp69, broadening
the binding capacity of the ligand to a region not previ-
ously involved for galactoside recognition by galectin-
7. The phenyl group itself does not seem to be involved
in the binding of ligand 6 despite being in close proxim-
ity to polar residues His33, Glu122 and Asn35. Inter-
estingly, His33 and Glu122 are not conserved among
galectins, thus focusing the ligand interaction towards
this position could offer better speciﬁcity of inhibition.
The anomeric sulfur atom can only weakly interact
with a water molecule (3.5 A ˚ ) stabilized by Arg31.
Interestingly, the benzyl moiety of the O-benzylphos-
phate 6 is not taking part in the inhibitor binding and
faces away from the protein surface. The absence of
interaction of the O-benzyl group is also reﬂected by
the similar, or slightly better, afﬁnity of the correspond-
ing methyl phosphate 5.
Furthermore, the difference in the crystal packing of
the ligand complex structure, highlighted by the differ-
ent crystallographic cell dimensions compared with the
native structure, may be explained by the ligand inter-
action with a symmetry-related molecule involving
residues Arg71 and Arg74 through two potential
hydrogen bonds with the phosphate group (Table 3,
Fig. S2). This symmetry-related molecule is unique to
molecule B of the asymmetric unit and may also
explain why only partial electron density was visible
for the ligand of molecule A.
Structural implications of inhibitor binding to
hGal-7
Determination of the crystal structure of hGal-7 in
complex with compound 6 supports our understanding
Table 2. X-ray data collection and reﬁnement statistics.
hGal-7 native hGal-7 + compound 6 complex
Data collection statistics
Space group P212121 P212121
Number of molecules⁄asymmetric unit 2 2
Cell dimensions a = 54.30, b = 65.11, c = 70.83 A ˚;
a = b = c =9 0  
a = 35.3, b = 53.5, c = 138.6 A ˚;
a = b = c =9 0  
Resolution range (A ˚) (outer shell) 50–1.38 (1.42–1.38) 49.88–1.67 (1.71–1.67)
Rsymm
a (%) 6.2 (31.6) 6.6 (13.4)
I⁄rI (outer shell) 25.0 (3.5) 20.4 (9.6)
Completeness (outer shell), % 97.5 (95.2) 92.9 (84.4)
Redundancy (outer shell) 5.3 (4.3) 4.3 (4.5)
Total no. of reﬂections 561 283 248 037
Unique no. of reﬂections 52 544 31 402
Wilson B factor (A ˚ 2) 18.8 15.1
Reﬁnement statistics
Resolution range (A ˚) 47.9–1.4 69.3–1.7
Rcryst
b (%) 18.1 20.4
Rfree
c (%) 22.6 23.9
Number of non-H atoms
Protein 2193 2205
Ligand 33
Water molecules 336 376
Average temperature factor (B factor) (A ˚ 2) 20 17.6
rmsd in bond lengths (A ˚) 0.01 0.01
rmsd in bond angles ( ) 1.26 1.08
a Rsymm = RhRi|I(h) ) Ii(h)|⁄RhRiIi(h), where Ii(h) and I(h) are the ith reﬂection and the mean measurements of the intensity of reﬂection h,
respectively.
b Rcryst = Rh|Fo ) Fc|⁄RhFo where Fo and Fc are the observed and calculated structure factor amplitudes of reﬂection h, respec-
tively.
c Rfree is equal to Rcryst for a randomly selected subset of reﬂections not used in the reﬁnement.
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thetic monosaccharide-based inhibitors (Table 1).
Compounds 5 and 6 showed the best afﬁnity for
hGal-7 with a similar Kd range (240 and 450 lM
respectively). These two molecules differ by the pres-
ence of the O-benzylphosphate group in 6 compared
with an O-methylphosphate group in 5. The O-benzyl-
phosphate was shown not to be involved in the bind-
ing; however, the smaller methyl group might be able
to interact with Arg31, possibly via a different orienta-
tion than that of the O-benzyl group, and hence show
a slightly better afﬁnity. The design of inhibitors with
modiﬁed (alkyl)-phosphate groups, e.g. at the 2-O
position, could be envisioned for a more favourable
interaction with Arg31 and other nearby residues.
Talose-based compounds structurally related to 2–6
have recently been described as inhibitors of other
galectins, including a taloside 7 (Table 1) that presents
the O-benzylphosphate group in a position different
from that of O-benzylphosphate 6 [32]. Inhibitors 6
and 7 differ at two more positions, in addition to the
inverted stereochemistry at the pyranose C2: the amide
group and anomeric sulfur atom. The ﬁrst is likely to
weaken the interactions with surrounding water mole-
cules, whereas substitution of S for O should not per-
turb the weak solvent-mediated contact with Arg31.
The taloside 7 has similar afﬁnity for galectin-7, which
suggests that inversion of the pyranose C2 results in
presentation of the 2-O-benzylphosphate in a similarly
favourable position.
Overall comparison with compound 2 demonstrates
that addition of a 2-O-phosphate moiety dramatically
improves the afﬁnity of the galactoside inhibi-
tors (Kd > 1m M). The presence of smaller (alkyl)
Fig. 1. Structures of the high resolution
hGal-7 and hGal-7 complex: previous hGal-7
structure (PDB code 1BKZ, red), hGal-7 high
resolution structure (blue), and hGal-7 in
complex with compound 6 (cyan, compound
6 not shown). Ribbon representation of the
three superposed structures with molecule
A and B of the dimer in the asymmetric
unit.
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interaction partners with residues from the hGal-7
CRD. Furthermore, the phenyl ring of the C3-benzam-
ido group was revealed not to be involved in the
ligand binding. This position on the inhibitor may,
however, have potential for improved galectin selectiv-
ity by targeting polar residues unique to hGal-7 away
from the CRD.
Discussion
Galectin-7 is an important member of the galactose-
binding family implicated in many pathological events.
The availability of detailed structural information on
the protein binding mechanism to its natural glycocon-
jugates has led to the development of synthetic inhibi-
tors with enhanced afﬁnity.
The high resolution structure of hGal-7 in complex
with the 2-O-benzylphosphate galactoside inhibitor 6
shows that the synthetic molecule has retained all the
conserved interactions involving the galactose moiety,
from which it is derived, as well as offering new inter-
actions. In particular, the phosphate group at the
galactose O-2 position is involved in additional hydro-
gen and water mediated bonds with Arg31 and Asn51
of the CRD. Investigation of additional substituents at
this position should lead to stronger inhibitors, consid-
ering the ﬂexibility of these residues and the adjacent
residue Arg53. The benzyl group appears to have no
interaction with the protein and is orienting itself away
from the CRD. This is to some degree analogous to
the binding of disaccharides to galectins and was also
observed with a galectin-1 inhibitor [16] where the sec-
ond carbohydrate moiety faces away from the protein
Fig. 2. Structure of hGal-7 in complex with compound 6. (A) hGal-7 surface (cyan) in complex with compound 6 (green). (B) hGal-7 (cyan)
in complex with compound 6 (green). Stereo ﬁgure with electron density showing compound 6 (at 1r level), residues involved in bind-
ing highlighted in stick and ball and water molecules in red spheres.
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power to the binding through its water-bonded sulfur
atom; substitutions of this group may create better
interaction with the protein, similar to earlier observa-
tions with substituted phenyl thio-galactosides [28].
On the other hand, the amido group of 6 is stabilizing
the other side of the ligand by water-mediated inter-
action allowing the phenyl group to extend across the
CRD. This position seems underexploited as galectin-7
presents a cluster of polar residues in a region showing a
strong solvent network in the apoprotein. Further inves-
tigation to replace the benzamido group might help
improve the inhibitor’s afﬁnity and selectivity toward
galectin-7, since this region of the protein is not particu-
larly conserved. A potent inhibitor of galectin-3 [33] car-
rying a 2,3,5,6-tetraﬂuoro-4-methoxybenzamido group
at C3¢ of lacNAc for example presented a stronger
afﬁnity due to an arginine–arene stacking and cation–p
interaction involving the C3¢-benzamido arene moiety.
The present structural study has highlighted the
potential of a novel 2-O-benzylphosphate galactoside
binding to hGal-7 (which is > 60-fold more potent
than its parent galactoside) and gives a template for
the design of stronger and selective galectin inhibitors.
Availability of such molecules is essential to further
reﬁne our knowledge of lectin–ligand binding and to
understand these proteins’ function and involvement in
severe pathologies for which potent drugs are required.
Experimental procedures
Cloning, expression and puriﬁcation of hGal-7
The gene coding for hGal-7 was obtained from RZPD
(#IRAKp961G19141Q2, Berlin, Germany) and cloned into
a modiﬁed pET-22 vector (Novagen, Darmstadt, Germany)
with a cleavable N-terminal poly-histidine tag. BL21 (DE3)
Escherichia coli cells were transformed with the recombi-
nant plasmid. Cells were grown at 37  Ct oa nA600 of
0.6–0.7, and then 0.5 mM isopropyl thio-b-D-galactoside
induction at 18  C was allowed for expression of the
recombinant protein. Cells were harvested 18 h after induc-
tion by centrifugation (4  C, 6 500 g). Induction of the
protein was analysed by SDS⁄PAGE.
Cell pellets were resuspended in lysis buffer (50 mM
sodium phosphate pH 8.0, 300 mM NaCl, 20 mM imidazole,
1m M phenylmethanesulfonyl ﬂuoride, 1 mgÆmL
)1 lyso-
zyme), incubated on ice for 10 min and sonicated for 10 min
by 30 s cycles. The preparation was then centrifuged for
30 min at 4  C, 10 000 g. The supernatant was loaded on a
5 mL HisTrap FF column (GE Healthcare, Uppsala,
Sweden) pre-equilibrated with wash buffer (50 mM sodium
phosphate pH 8.0, 300 mM NaCl, 20 mM imidazole). The
column was washed extensively and a single step elution
(50 mM sodium phosphate pH 8.0, 300 mM NaCl, 250 mM
imidazole) was carried out. The eluted fraction was dialysed
overnight in wash buffer at 4  C. The N-terminal histidine
tag was removed by HRV3C (Novagen, Darmstadt,
Germany) cleavage for 18 h at 4  C and the reaction was
loaded onto a 1 mL HisTrap FF column (GE Healthcare,
Uppsala, Sweden). The unbound fraction was collected and
Fig. 3. Comparison with galactose binding to hGal-7. hGal-7 in com-
plex with compound 6 (cyan, green respectively) superposed with
hGal-7 in complex with galactose (PDB code 2GAL, yellow). Resi-
dues involved in ligand interaction are highlighted in stick and ball.
Table 3. Hydrogen bond interactions between hGal-7, compound 6
and b-galactose (PDB: 2GAL).
hGal-7 Compound 6
Distance
(A ˚)
b-galactose
(PDB: 2GAL)
Distance
(A ˚)
Asn51 OD1 O4A 3.0 O4A 3.2
His49 NE2 O4A 2.8 O4A 2.9
Arg53 NH2 O4A 3.0 O4A 3.2
Arg53 NH2 O5A 3.1 O5A 3.1
Glu72 OE2 O6A 2.8 O6A 2.5
Asn62 ND2 O6A 2.8 O6A 2.9
Arg31 NH1 O2P 3.4
Water O1P 2.9
Water O2P 2.7
Water O1B 2.7
Water O1B 3.1
Arg74
N(sym)
O3P 2.8
Arg71
NH1(sym)
O2P 2.6
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before loading on a gel ﬁltration column (Superdex 200; GE
Healthcare, Uppsala, Sweden) pre-equilibrated with ﬁnal
buffer (50 mM Tris pH 8.0, 200 mM NaCl). A single peak
elution was analysed by SDS⁄PAGE and showed a band of
pure hGal-7 at 15 kDa.
Inhibitors and galectin-7 afﬁnities
Synthesis of compounds 2–6 [29] and 7 [32] have been
described in detail earlier and evaluation as galectin-7
inhibitors was performed as earlier reported [29].
Crystallization
Crystals of recombinant hGal-7 were grown by the hanging-
drop method, the protein at 10 mgÆmL
)1 in 50 mM Tris pH
8.0, 200 mM NaCl, against a reservoir solution containing
50 mM sodium phosphate pH 8.0, 300 mM NaCl, 20 mM
imidazole and 17% poly(ethylene glycol) 3350. Single crystals
appeared after 2 days at 16  C. A complete data set to 1.4 A ˚
was collected from one crystal in space group P212121, with
unit cell dimensions a = 54.30, b = 65.11, c = 70.83 A ˚ ,
and two hGal-7 molecules per asymmetric unit.
hGal-7 was incubated with 2 mM compound 6 for 2 h at
room temperature before being set up for crystallization.
Cocrystals of the complex were obtained by the hanging-
drop method against 100 mM Bistris-propane pH 8.5,
200 mM sodium formate and 20% poly(ethylene glycol)
3350. Single crystals appeared after 24 h at 16  C. A com-
plete data set to 1.7 A ˚ was collected from one crystal in
space group P212121, with unit cell dimensions a = 35.3 A ˚ ,
b = 53.5 A ˚ , c = 138.6 A ˚ , and two hGal-7 molecules per
asymmetric unit.
Data collection and structure determination
Data were collected at the Diamond Light Source (Oxford,
UK), beamlines IO3 and IO4 which were equipped with a
Quantum-4 CCD detector (Area Detector Systems Corpo-
ration, Poway, California, USA). Crystals were soaked in
25% poly(ethylene glycol) 3350 as cryoprotectant prior to
data collection. The data were processed using HKL2000
[34] (Table 2).
Initial phases were obtained by the molecular replacement
method using PHASER [35,36] with the coordinates of hGal-7
(PDB: 1BKZ). Crystallographic reﬁnement was carried out
using REFMAC5 version 5.5 [35,37], and SHELXP version 97-3
[38] for anisotropic reﬁnement of the high resolution hGal-7
structure. Model ﬁtting was done using COOT version 0.6
[39]. The program MOLPROBITY [40] was used to check for
validation of the structure. Detailed statistics for the reﬁned
structure of hGal-7 and its complex are given in Table 2.
Figures were drawn with PYMOL (The PyMOL Molecular
Graphics System, Version 1.3, Schro ¨ dinger, LLC, New York,
NY, USA).
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Fig. S1. Structure of high resolution hGal-7–Cys38.
Positive electron density at Cys38 molecule A.
Fig. S2. Structure of hGal-7 in complex with com-
pound 6. Crystallographic symmetry interface interact-
ing with compound 6 and involving residues Arg71
and Arg74 through two potential hydrogen bonds with
the phosphate group.
This supplementary material can be found in the
online version of this article.
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